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Summary 
This report provides information about Australia’s health-care expenditure on arthritis and 
other musculoskeletal conditions, including that on patterns of expenditure by health-care 
sector, type of musculoskeletal condition, age group, sex and over time.  
The main findings of the report are that, in 2008–09: 
• In Australia, estimated health-care expenditure on arthritis and other musculoskeletal 
conditions totalled $5,690 million—the fourth most expensive disease group, accounting 
for 9% of total health-care expenditure allocated to hospital admitted patient services, 
out-of-hospital medical services and prescription pharmaceuticals ($65,129 million). 
• Osteoarthritis accounted for 29% of health-care expenditure on arthritis and other 
musculoskeletal conditions ($1,637 million), followed by back problems ($1,177 million 
or 21%), rheumatoid arthritis ($355 million or 6%) and osteoporosis ($306 million or 5%). 
The remaining expenditure (39%) was distributed across the broad range of ‘other’ 
musculoskeletal conditions. 
• More than half (54%) of the health-care expenditure on arthritis and other 
musculoskeletal conditions was on hospital admitted patient services ($3,091 million), 
followed by 30% on out-of-hospital medical expenses ($1,677 million) and 16% on 
prescription pharmaceuticals ($922 million). 
• The pattern of expenditure across health-care sectors varied markedly among 
musculoskeletal conditions. For example, the majority of expenditure for rheumatoid 
arthritis and osteoporosis was on pharmaceuticals (77% and 63%, respectively) and the 
largest proportion for osteoarthritis was on admitted patient hospital services (77%).  
• Health-care expenditure on arthritis and other musculoskeletal conditions was greatest 
for people aged 65–74 ($1,245 million) although the per person expenditure was highest 
for people aged 75–84 (an average of $1,007 per person aged 75–84).  
• Health-care expenditure on these arthritis and other musculoskeletal conditions overall 
was higher for females than males (an average of $301 per female compared with $229 
per male). 
It is difficult to compare absolute expenditure estimates over time due to data limitations 
and method changes; however, the patterns of expenditure by health sector have remained 
relatively stable, with expenditure on hospital admitted patient services being the dominant 
component of expenditure at all three time points in recent estimates (2000–01, 2004–05 and 
2008–09).  
Data are drawn from the AIHW Disease Expenditure Database, with a focus on estimates for 
2008–09, the most recent year for which data are available.  
The term ‘expenditure’ used in this report refers to expenditure through the health system 
that can be allocated by disease, and covers about 70% of total health-care expenditure in 
Australia. This method has various limitations, described in detail in the report, which mean 
that that the expenditure information presented here underestimates the total cost of arthritis 
and other musculoskeletal conditions to the community. While these limitations affect the 
absolute estimates of disease expenditure (total dollars), they do not notably affect the 
relative expenditure (or rankings) across disease groups.  
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1 Introduction 
This report presents information about Australia’s health-care expenditure on arthritis and 
other musculoskeletal conditions in 2008–09. This includes information on patterns of 
expenditure by health-care sector, type of musculoskeletal condition, age group, sex and 
over time.  
Arthritis and other musculoskeletal conditions are a diverse group of over 150 different 
conditions, including various forms of arthritis, back problems and osteoporosis (WHO 
Scientific Group 2003).  
This report presents detailed expenditure estimates for four conditions: osteoarthritis, 
rheumatoid arthritis, back problems and osteoporosis, with other conditions not covered by 
these categories presented under the heading ‘other’ musculoskeletal conditions. A brief 
overview of these musculoskeletal conditions is provided in Box 1.1. 
Box 1.1: Arthritis and other musculoskeletal conditions covered in this report 
Osteoarthritis: A degenerative joint condition that mostly affects the hands, spine and 
joints such as the hips, knees and ankles. Its main feature is the breakdown of the cartilage 
that overlies the ends of the bones in the joints. Age is the strongest factor in the 
development and progression of osteoarthritis. Other more modifiable risk factors are being 
overweight, physical inactivity, joint trauma and repetitive joint loading tasks (for example, 
kneeling, squatting and heavy lifting). 
Rheumatoid arthritis: A chronic disease marked by inflammation of the joints, most often 
affecting the hand joints in a symmetrical fashion (that is, both sides of the body are affected 
at the same time). The immune system attacks the tissues lining the joints, causing pain, 
swelling and stiffness. Over time there is progressive and irreversible joint damage, 
resulting in deformities and severe disability. The exact cause of rheumatoid arthritis is not 
well understood although there is a strong genetic component. 
Back problems: Back problems are a range of conditions related to the bones, joints, 
connective tissue, muscles and nerves of the back. Back problems here include back pain or 
problems where there is no identifiable cause or diagnosis, disc disorders, sciatica and 
curvature of the spine. The occurrence of back problems can be associated with several 
factors such as age, physical fitness, smoking, being overweight and type of occupation (for 
example, those requiring lifting, bending, twisting, pulling and pushing).  
Osteoporosis: Thinning and weakening of bones often occurs with age, increasing the risk 
of fracture. Osteoporosis occurs in both sexes but is more common in women. The risk 
factors associated with the development of osteoporosis include increasing age, female sex, 
family history of the condition, low vitamin D levels, low intake of calcium, low body 
weight, smoking, excess alcohol consumption, physical inactivity, long-term corticosteroid 
use and reduced oestrogen levels.  
‘Other’ musculoskeletal conditions: These include specific conditions such as gout, juvenile 
arthritis, ankylosing spondylitis and systemic lupus erythematosus and broad categories 
such as systemic connective tissue disorders, soft tissue disorders, osteopathies and 
chondropathies, and other disorders of the musculoskeletal system and connective tissue. 
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Arthritis and other musculoskeletal conditions are very common in Australia, affecting more 
than one-quarter of Australians or 6.1 million people (28% of the total population) in 2011–12 
(ABS 2012). The most commonly reported musculoskeletal conditions are arthritis (including 
osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis and other forms of arthritis), 
affecting an estimated 3.3 million people; back problems (affecting 3 million people, 
including 1.8 million people with back pain/back problems not further classified and 
1.2 million people reporting diagnosed disc disorders, sciatica or curvature of the spine); and 
osteoporosis, affecting 728,000 people. Arthritis and other musculoskeletal conditions 
(particularly back problems) are most common among the older population, but are also 
experienced by younger age groups (Figure 1.1). 
 
 
Note: Prevalence for all ages is age-standardised to the Australian population as at 30 June 2001. ‘Back problems’ includes ABS  
categories back pain/problems not elsewhere classified, disc disorders, sciatica and curvature of the spine. 
Source: AIHW analysis of ABS National Health Survey 2011–12 (unpublished). 
Figure 1.1: Prevalence of arthritis and other musculoskeletal conditions, by age group, 2011–12 
Arthritis and other musculoskeletal conditions may have a substantial impact on the health 
and quality of life of those affected. While rarely a direct cause of death, these conditions are 
a major cause of pain, fatigue, deformity, mobility limitations and functional impairment (for 
example, difficulty gripping, lifting, climbing stairs). They are a major cause of disability, 
with 44% of all people with arthritis and other musculoskeletal conditions reporting activity 
limitations in daily tasks such as self-care and mobility (AIHW 2012). 
The overall burden of these conditions is high, both in Australia and internationally. For 
example, according to the Global Burden of Disease 2010 Study, the burden of low back pain 
is ranked sixth in the world and first in Australasia (Australia and New Zealand); neck pain, 
twenty-first in the world and tenth in Australasia; and osteoarthritis, thirty-eighth in the 
world and twenty-third in Australasia (Hoy et al. 2014a, 2014b; Murray et al. 2012). 
The ongoing management of musculoskeletal conditions involves a combination of 
self-management, primary care (that is, care provided by general practitioners (GPs) and 
allied health service providers such as physiotherapists, exercise physiologists, pharmacists 
and podiatrists), care delivered by medical specialists in the community, care provided in 
hospitals and prescribed medication.  
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2 Methods and limitations 
Generally, the method for estimating disease expenditure is a mixture of ‘top-down’ and 
‘bottom-up’ approaches, where total expenditure across the health system is estimated and 
then allocated to the relevant conditions based on the available service use data. This method 
yields consistency, good coverage and totals that add up to known expenditure but it is not 
as comprehensive for any specific disease as a detailed ‘bottom-up’ analysis, which would 
include the actual costs incurred for that disease. In most cases, however, a lack of data 
means that a more granular ‘bottom-up’ analysis is not possible. 
In interpreting this report, readers should be aware that ‘expenditure’ estimates refer only to 
the 70% of total recurrent health-care expenditure (that is, non-capital expenditure on health 
goods and services through the health system) in Australia that can be allocated to disease 
groups. A summary of the inclusions and exclusions of the Australian Institute of Health and 
Welfare (AIHW) Disease Expenditure Database, as applied to the health conditions in this 
report, is provided in Table 2.1. Further details on methods and limitations are included in 
this chapter and at Appendix B. 
The AIHW Disease Expenditure Database 
The main source of information for this report is the AIHW Disease Expenditure Database. It 
provides a broad picture of the use of health system resources classified by disease group, 
and is a reference source for planners and researchers interested in costs and use patterns for 
particular disease groups. This information is also useful for comparing expenditure for 
different diseases and for ranking diseases by levels of expenditure.  
Estimates in the Disease Expenditure Database are derived by combining information from 
the National Hospital Morbidity Database (NHMD), the National Public Hospitals 
Establishments Database (NPHED), the Health Expenditure Database, the National Hospital 
Cost Data Collection (NHCDC) and the Bettering the Evaluation and Care of Health 
(BEACH) survey.  
The Disease Expenditure Database contains estimates of expenditure by disease category, 
age group and sex for admitted patient hospital services, out-of-hospital medical expenses, 
prescription pharmaceuticals, optometry and dental services, community mental health 
services and public health cancer screening.  
The areas of expenditure that apply to arthritis and other musculoskeletal conditions—and 
hence are included in this report—are: 
• hospital admitted patient services 
• out-of-hospital medical expenses  
• prescription pharmaceuticals. 
Funding for these health-care sectors comes from both government and non-government 
sources (including private health insurance and individuals).  
The AIHW is continually seeking to improve the methods used to produce these estimates. 
As a consequence, disease expenditure estimates are subject to revision and the most recently 
published results may not be directly comparable with previously published data.  
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A data quality statement for the Disease Expenditure Database is at Appendix B. It provides 
further information on aspects of the quality of the data being reported by the AIHW and is 
included to help readers understand the limitations of the data and make informed 
judgments about their use of the data. 
Health-care expenditure exclusions and other data limitations 
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure on non-admitted hospital patient services and most community and public 
health programs, for instance, which support the treatment and prevention of many 
conditions, cannot be allocated to one specific disease or injury. This is also true of capital 
expenditure on health facilities and equipment.  
Table 2.1 summarises the areas for which health expenditure can (inclusions) and cannot 
(exclusions) be allocated by disease in the 2008–09 Disease Expenditure Database. Further 
details on specific areas of expenditure also follow.  
Readers need to bear in mind that cost-of-illness data provide estimates only of the impact a 
disease has on health-care expenditure. The estimates of the cost of treating and/or 
preventing a disease cannot be used to indicate the loss of health due to that disease.  
For example, indirect costs such as loss of productivity related to illness, and costs associated 
with lost productivity due to carers having to take time off to care for a person with arthritis 
or another musculoskeletal condition, are not included in the Disease Expenditure Database. 
They are, however, likely to constitute a high financial burden for people with these 
conditions and their families, friends and society in general, through lost productivity and 
the considerable cost of ongoing management and treatment. 
Care should be taken not to interpret expenditure associated with disease treatment as 
simply an estimate of the savings that would result from prevention of disease. Conversion 
of the opportunity cost—or the benefits forgone—of resources being devoted to disease 
treatment into expenditure savings involves a number of additional considerations. See, for 
example, Disease costing methodology used in the disease costs and impact study 1993–94 (AIHW: 
Mathers et al. 1998).  
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Table 2.1: AIHW Disease Expenditure Database: inclusions and exclusions for analysis presented 
in this report 
Area of expenditure Inclusions Exclusions 
Hospital expenses Cost of services for admitted patients in: 
• public hospitals 
• private acute hospitals 
• psychiatric hospitals 
• medical services provided to private 
admitted patients in hospitals 
Costs for: 
• non-admitted patient hospital services 
• Highly Specialised Drugs  
Out-of-hospital medical 
expenses 
Cost of services provided by, or on behalf of, 
registered medical practitioners that are 
funded by: 
• Medicare Benefits Schedule (MBS) 
• Department of Veterans Affairs 
• compulsory motor vehicle third-party 
insurance 
• workers’ compensation insurance 
• private health insurance funds 
• Australian Government premium rebates 
allocated to medical services 
• MBS co-payments and other  
out-of-hospital pocket payments 
• non-MBS medical services (such as 
provision of vaccines for overseas travel) 
Costs for: 
• medical services provided to public 
patients at outpatient clinics in public 
hospitals 
• residential aged care 
• other health practitioner services  
• community health services expenditure  
• expenditure on public health programs  
• health administration, health aids and 
appliances, and patient transport 
(ambulance) 
Pharmaceuticals Costs for: 
• pharmaceuticals under the 
Pharmaceutical Benefits Scheme (PBS) 
• Repatriation Pharmaceutical Benefits 
Scheme (RPBS) 
• under co-payment prescriptions (those 
pharmaceuticals listed in the PBS and 
RPBS, the total costs of which are equal 
to or less than the statutory patient 
contribution for the class of patient 
concerned) 
• private prescriptions (pharmaceuticals 
dispensed through private prescriptions 
that do not fulfil the criteria for payment or 
benefit under the PBS or RPBS) 
Costs for over-the-counter drugs (including 
pain medications, vitamins, herbal and other 
complementary medicines) 
Capital costs Nil Excluded because not possible to allocate to 
specific diseases 
Indirect costs Nil Costs include: 
• loss of productivity 
• travel costs of patients 
• costs incurred by carers and family 
• informal community care costs 
• costs relating to lost quantity and quality 
of life 
• community non-health services costs (for 
example, home help, Meals on Wheels) 
Hospital admitted patient services 
Expenditure on hospital admitted patient services refers to the cost of services for admitted 
patients in both public and private acute hospitals and psychiatric hospitals, as well as 
expenditure on medical services provided to private admitted patients in hospitals.  
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Expenditure on hospital admitted patient services is based on hospitalisations (episodes of 
care) using the principal diagnosis for each hospitalisation, with diagnosis information 
coded to the International Classification of Diseases, Tenth Revision, Australian Modification 
(ICD-10-AM). No expenditure is allocated for additional diagnoses recorded during these 
hospitalisations. This means that, for example, health complications, such as fractures 
associated with osteoporosis, are not included in the musculoskeletal expenditure 
component unless osteoporosis is classified in the underlying hospital data as the principal 
diagnosis.  
In this report, expenditure was assigned to arthritis and other musculoskeletal conditions 
when the principal diagnosis was between ICD-10-AM codes M00 and M99. The codes used 
for specific conditions are listed in Table 2.2. It should be noted that grouping a large number 
of diseases for analytical purposes, as has been done with ‘other’ musculoskeletal conditions, 
has the potential to mask expenditure patterns for individual diseases within this group. 
Table 2.2: ICD-10-AM codes used for arthritis and other musculoskeletal conditions 
Condition ICD-10-AM codes 
Osteoarthritis M15–19 
Rheumatoid arthritis M05–06; M08 
Back problems M46.4; M46.9; M47; M48.0–48.2; M48.8–48.9; M50; M51; M53; M54 
Osteoporosis M80–82 
‘Other’ musculoskeletal conditions Remaining of above unallocated M00–M99 codes 
All musculoskeletal conditions M00–M99 (the above disease codes are subcomponents of the group) 
Expenditure on Highly Specialised Drugs in hospitals has not been included in the AIHW 
Disease Expenditure Database. 
Out-of-hospital medical expenses and prescription pharmaceuticals 
The prevention, management and treatment of arthritis and other musculoskeletal 
conditions beyond hospital settings cannot be examined in detail because there is very little 
or no information about primary health care activity in relation to arthritis and other 
musculoskeletal conditions. Except for data collected about GP activity through the BEACH 
survey, there is very little information on primary health care activity (such as public and 
private allied health services, state-funded community health services, pharmacy, ambulance 
and tele-health services) or specialist consultations. Similarly, while prescription 
pharmaceutical data can be used in some specific circumstances to better understand disease 
management, it is limited because it lacks information about the diagnosis for which the 
medication was prescribed.  
Expenditure estimates for out-of-hospital medical expenses and prescription 
pharmaceuticals presented in this report are derived using the BEACH survey in conjunction 
with data from other sources including the MBS, PBS, RPBS, and script volumes for private 
and under co-payment drugs. (Under co-payment drugs are those pharmaceuticals listed in 
the PBS or RPBS, the total costs of which are equal to or less than the statutory patient 
contribution for the class of patient concerned.) The BEACH data were collected by the 
Family Medicine Research Centre of the University of Sydney under a previous collaboration 
with the AIHW. BEACH is a sample survey of GPs and their encounters with patients. It is 
subject to the inherent limitations of a survey methodology, including questions about how 
representative the survey is of the target population. Hence, results based on BEACH 
analysis should be interpreted cautiously. 
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For out-of-hospital medical expenses, the BEACH survey data were aggregated over 3 years 
to ensure the sample size was sufficiently large to perform the analysis required. The 
aggregated data were used to estimate the proportion of GP encounters in which a 
musculoskeletal condition was a ‘problem managed’. This proportion was then applied to 
the MBS data for the reference year. Based on this method, expenditure can be allocated for 
GP visits and referrals to medical specialists, pathology and imaging, referred to throughout 
this report as out-of-hospital medical expenses. 
For prescription pharmaceuticals, the BEACH survey data were aggregated over 3 years to 
allocate expenditure on prescription drugs to each disease group, based on the problems 
managed in the GP encounter that related to the prescribing of a particular drug. The 
Anatomical Therapeutic Chemical Classification System codes were mapped to codes for 
prescription drugs used in the BEACH survey. Relevant proportions were applied to data 
from the PBS and the RPBS, which describe pharmaceuticals for which benefits have been 
paid or are payable. Also included are the costs for under co-payment prescriptions and 
private prescriptions. (As indicated above, under co-payment prescriptions are those 
pharmaceuticals listed in the PBS or RPBS, the total costs of which are equal to or less than 
the statutory patient contribution for the class of patient concerned. Private prescriptions are 
those pharmaceuticals dispensed through private prescriptions that do not fulfil the criteria 
for payment or benefit under the PBS or RPBS.)  
The method for distributing prescription medicines expenditure by disease relies entirely on 
general practice prescription data. For diseases where a considerable proportion of 
prescriptions are made by medical specialists, this may not accurately reflect prescription 
medicine expenditure because it assumes that prescribing patterns for GPs and medical 
specialists are the same.  
Per person expenditure 
All per person calculations of expenditure in this report have been derived using the whole 
Australian population as at 30 December 2008 as the denominator (ABS 2013). This method 
has been adopted to align with other related expenditure reporting (for example, AIHW 
2014a) and to avoid reliance on self-reported prevalence data from the Australian Bureau of 
Statistics (ABS) National Health Survey (NHS) for specific musculoskeletal diseases.  
This approach results in much lower per person costs than would have been the case if the 
numbers of people who had the disease (prevalence data) had been used. The method used 
here, however, does provide a valid measure of per capita expenditure that can be used to 
compare both individual diseases and results over time. 
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3 How much is spent on arthritis and 
other musculoskeletal conditions in 
Australia? 
Overall expenditure 
In 2008–09, arthritis and other musculoskeletal conditions accounted for 8.7% of estimated 
health-care expenditure allocated to disease groups in Australia—that is, $5,690 million of 
the $65,129 million spent for all diseases allocated to hospital admitted patient services, 
out-of-hospital medical services and prescription pharmaceuticals. This is the fourth highest 
disease group in terms of national expenditure (Figure 3.1).  
Cardiovascular disease accounted for the highest proportion of health-care expenditure in 
2008–09 followed by oral health and mental disorders (Figure 3.1). 
 
Notes 
1.  This figure uses 2003 burden of disease coding so that all major disease groups could be included. It should be noted that data based  
on burden of disease codes may produce slightly different proportions of total expenditure from those derived using different groupings of  
ICD-10-AM codes. 
2.  Percentages do not add up to 100 because not all diseases are included. 
Source: Disease Expenditure Database, AIHW. 
Figure 3.1: Proportion of health-care expenditure by disease group, 2008–09 
Of the estimated health-care expenditure for arthritis and other musculoskeletal conditions 
in 2008–09, osteoarthritis accounted for 29%, back problems 21%, rheumatoid arthritis 6% 
and osteoporosis 5%. The remaining expenditure (39%) was distributed across the broad 
range of ‘other’ musculoskeletal conditions (Figure 3.2). 
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Source: Disease Expenditure Database, AIHW. 
Figure 3.2: Expenditure by type of arthritis and other musculoskeletal conditions, 2008–09 
Expenditure by health-care sector 
Estimated health-care expenditure on arthritis and other musculoskeletal conditions in  
2008–09 consisted of: 
• 54% on hospital admitted patient services ($3,091 million) 
• 30% on out-of-hospital medical expenses (includes GP and specialist consultations, 
imaging, pathology and other diagnostic services) ($1,677 million) 
• 16% on prescription pharmaceuticals ($922 million) (Table 3.1). 
Table 3.1: Arthritis and other musculoskeletal conditions and all disease expenditure by 
health-care sector, 2008–09 ($ million) 
 Arthritis and other 
musculoskeletal conditions(a) 
 
All diseases 
Health-care sector $m %  $m % 
Hospital admitted patient services(b) 3,091 54.3  38,675 59.4 
Out-of-hospital medical expenses(c) 1,677 29.5  15,871 24.4 
Prescription pharmaceuticals(d) 922 16.2  10,583 16.2 
Total allocated expenditure 5,690 100.0  65,129 100.0 
(a)  Includes musculoskeletal conditions coded in the ICD-10-AM as M. 
(b)  Expenditure for hospital admitted patient services for arthritis and other musculoskeletal conditions includes only cases where the principal 
diagnosis by ICD-10-AM was between M00 and M99. 
(c)  Out-of-hospital medical expenses and prescription pharmaceuticals rely on sample survey data that can vary from year to year. 
(d)  Includes all medicines for which a prescription is needed, including PBS/RPBS benefit-paid prescriptions plus private prescriptions and under 
co-payment prescriptions. Excludes over-the-counter pharmaceuticals. 
Source: Disease Expenditure Database, AIHW. 
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Hospital admitted patient services 
In 2008–09, hospital admitted patient services accounted for 54% of estimated health-care 
expenditure on arthritis and other musculoskeletal conditions. Of the $3,091 million spent on 
these services, the greatest proportion was for osteoarthritis (41%), followed by ‘other’ 
musculoskeletal conditions (38%), back problems (18%), osteoporosis and rheumatoid 
arthritis (each 1%) (Table 3.2). 
Expenditure on hospital admitted patient services was based on admitted patients only and 
therefore excludes closely related expenditure on hospital emergency department or 
outpatient clinic services. Treatment in hospitals represents a significant component of care 
for some musculoskeletal conditions (for example, rheumatoid arthritis) (AIHW 2010). 
Table 3.2: Expenditure by health-care sectors, type of arthritis and other musculoskeletal 
conditions, 2008–09 ($ million) 
 
Hospital 
admitted patient 
services 
Out-of-hospital 
medical 
expenses 
Prescription 
pharmaceuticals 
Total 
expenditure 
($m) 
Per cent of total 
expenditure for 
musculoskeletal 
conditions Type of condition $m % 
 
 
$m % 
 
 
$m % 
Osteoarthritis 1,256 40.6 282 16.8 99 10.7 1,637 28.8 
Rheumatoid 
arthritis 44 1.4 37 2.4 275 29.8 355 6.2 
Back problems 560 18.1 465 27.7 153 16.6 1,177 20.7 
Osteoporosis 43 1.4 68 4.1 194 21.0 306 5.4 
Other musculo-
skeletal conditions 1,188 38.4 825 49.2 201 21.8 2,214 38.9 
All arthritis and 
other musculo-
skeletal 
conditions 3,091 100.0 1,677 100.0 922 100.0 5,690 100.0 
Note: Components may not sum to the total due to rounding. 
Source: Disease Expenditure Database, AIHW. 
Out-of-hospital medical expenses 
Out-of hospital medical expenses accounted for $1,677 million or 30% of estimated 
health-care expenditure on arthritis and other musculoskeletal conditions in 2008–09. The 
largest proportion of these expenses was for ‘other’ musculoskeletal conditions (49%), 
followed by back problems (28%), osteoarthritis (17%), osteoporosis (4%) and rheumatoid 
arthritis (2%) (Table 3.2). 
Arthritis and other musculoskeletal conditions are mainly managed in primary health care, 
sometimes by a multidisciplinary team of clinicians and allied health professionals (mainly 
for osteoarthritis and rheumatoid arthritis) (Arthritis Australia 2014a; RACGP 2009a). These 
conditions are believed to be one of the most commonly managed problems in general 
practice, with survey data suggesting that musculoskeletal conditions were managed by GPs 
in approximately 18 per 100 GP–patient encounters in 2012–13 (Britt et al. 2013). Of these, 
2.9 per 100 GP–patient encounters were for back problems, 2.8 for osteoarthritis, 0.8 for 
osteoporosis and 0.5 for rheumatoid arthritis. The remaining 11% were for other diverse 
musculoskeletal conditions, such as sprains, fractures and injuries.  
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The estimates presented here are likely to underestimate out-of-hospital medical expenses 
for these conditions quite markedly. This is due to the current lack of national information 
about non-GP primary health care activity and associated expenditure (for example, about 
private allied health and state/territory-funded community health activity).  
Prescription pharmaceuticals 
Prescription pharmaceuticals accounted for $922 million or 16% of the estimated health-care 
expenditure for arthritis and other musculoskeletal conditions in 2008–09. Rheumatoid 
arthritis accounted for the largest proportion of this (30%) followed by ‘other’ 
musculoskeletal conditions (22%), osteoporosis (21%), back problems (17%) and 
osteoarthritis (11%) (Table 3.2). 
Medications, both prescribed and over-the-counter, are widely used to treat and manage 
arthritis and other musculoskeletal conditions. The most common prescribed pharmaceutical 
medications—non-steroidal anti-inflammatory drugs (NSAIDs)—offer relief from 
inflammation, reduce swelling and increase mobility. Table 3.3 lists the most common 
medications prescribed by GPs for arthritis and other musculoskeletal conditions in 2012–13. 
Table 3.3: Common medications prescribed by GPs for arthritis and other musculoskeletal 
conditions, 2012–13 
Type of medication 
Per cent of all prescribed 
medications Rate per 100 encounters  
Anti-inflammatory and anti-rheumatic products, 
non-steroidal 
3.5 3.0 (2.8–3.1) 
 Meloxicam 1.0 0.8 (0.7–0.9) 
 Diclofenac 0.7 0.6 (0.5–0.7) 
 Celicoxib 0.7 0.6 (0.5–0.6) 
Anti-gout preparations 0.7 0.5 (0.5–0.6) 
Drugs affecting bone structure and mineralisation 0.6 0.5 (0.4–0.6) 
Total musculoskeletal system prescriptions 5.0 4.2 (3.9–4.4) 
Source: Britt et al. 2013. 
Australian guidelines also recommend intra-articular corticosteroid injections for short-term 
treatment of hip and knee osteoarthritis (Arthritis Australia 2014b; RACGP 2009b). Due to 
data limitations, expenditure on these injections is captured only where they are provided as 
part of an admitted patient hospital stay although a small amount of this treatment is 
delivered in primary care settings by specially trained GPs.  
For rheumatoid arthritis, newer types of disease-modifying anti-rheumatic drugs (DMARDs) 
called biologic disease-modifying anti-rheumatic drugs (bDMARDs) play an important role 
in altering the disease’s progression (AIHW 2013). These pharmaceuticals can be prescribed 
by rheumatologists only under strict eligibility criteria. Expenditure on these medications is 
not fully captured in the disease expenditure estimates due to a lack of data on the 
prescribing patterns of specialists.  
The most common pharmaceuticals for managing osteoporosis are bisphosphonates, 
analgesics and synthetic hormones (AIHW 2011). Bisphosphonates, also known as 
anti-resorptive medicines, reduce the likelihood of adverse outcomes of osteoporosis, such as 
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fragility fractures and associated morbidity, disability and mortality, by slowing further loss 
of bone mineral density (National Osteoporosis Foundation 2012).  
Non-prescription medications and supplements such as paracetamol, glucosamine and fish 
oil are also commonly used in managing osteoarthritis and other musculoskeletal conditions. 
Information about these expenses is not captured in the expenditure data used in this report.  
Overall, estimates for pharmaceutical expenditure on these conditions are therefore an 
underestimate of the real costs involved.  
 
  Health-care expenditure on arthritis and other musculoskeletal conditions 2008–09 13 
4 How does expenditure vary by type of 
musculoskeletal condition? 
Because of the diverse nature of arthritis and musculoskeletal conditions, treatment and 
management vary markedly across their different types. This is reflected in the patterns of 
expenditure across health-care sectors for each type of arthritis and other musculoskeletal 
condition (Figure 4.1). 
 
Source: Disease Expenditure Database, AIHW. 
Figure 4.1: Distribution of expenditure for arthritis and other musculoskeletal conditions, by 
health-care sectors, 2008–09 
Osteoarthritis 
In 2008–09, $1,637 million was spent on osteoarthritis, with hospital admitted patient services 
accounting for the largest proportion (77%) of health-care expenditure (Table C3, 
Appendix C). A large proportion of this expenditure is likely to be for: 
• joint replacement surgery associated with severe osteoarthritis that has not responded to 
other treatment and management such as medication and exercise 
• ‘arthroscopy’ performed in the early stages of osteoarthritis for temporary symptom 
relief and to diagnose the reason for the pain and damage to the joint. 
For example, according to the AIHW NHMD, in 2008–09, there were 88,157 hospitalisations 
with a principal diagnosis of osteoarthritis during which 49,893 joint replacements 
(30,406 knee replacements and 19,487 hip replacements) and 21,456 ‘knee arthroscopies’ 
(arthroscopic procedures of the knee) were performed. (See Appendix A for further details of 
procedure types.) 
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The number of total joint replacements for people with a principal diagnosis of osteoarthritis 
increased over the 10 years to 2011–12 (AIHW 2014b). However, the rate of knee 
arthroscopies for people with osteoarthritis appears to have remained relatively stable at the 
national level over this period. 
Knee arthroscopy is a very common orthopaedic procedure. Although the efficacy of this 
procedure for people with osteoarthritis has previously been questioned (Laupattarakasem 
et al. 2008; Moseley et al. 2002), there are reports of its increasing use over time in the United 
Kingdom and United States (Hawker et al. 2008; Kim et al. 2011). There have been mixed 
findings about trends over time in the use of this procedure in various Australian 
jurisdictions, settings and diagnosis groups. While rates of the procedure declined between 
2000 and 2009 in Victoria, this decline was not apparent for people with osteoarthritis 
(Bohensky et al. 2012). A study of New South Wales patients found that overall procedure 
rates for knee arthroscopy did not decline between 2000 and 2008 (although there was a 
decline in the rates performed in public hospitals). This study also found that, for the patient 
group of people aged 65 or more, use of knee arthroscopy was associated with a sizeable 
reduction in total knee arthroplasty (replacement) within 24 months of the knee arthroscopy 
(Harris et al. 2013).  
Out-of-hospital medical expenses accounted for 17% of health-care expenditure for 
osteoarthritis in 2008–09 and prescription pharmaceuticals, 6%. 
Back problems 
Of the $1,177 million health-care expenditure attributable to back problems in 2008–09,  
48% was for hospital admitted patient services, reflecting that hospital treatment and 
management of back problems are common (Table C3, Appendix C). According to the 
NHMD, in 2008–09, there were 87,272 hospitalisations with a principal diagnosis of back 
problems.  
Out-of-hospital medical expenses accounted for 39% of the health-care expenditure for back 
problems ($464 million) and prescription pharmaceuticals for 13% ($153 million) in 2008–09. 
As with other musculoskeletal conditions predominantly managed outside hospital settings, 
these figures are likely to markedly underestimate the real expenditure on back problems. 
This underestimation is due to the substantial use of over-the-counter pain relief medications 
and the use of allied health services such as physiotherapy, for which expenditure estimates 
cannot be generated or allocated to disease groups.  
Rheumatoid arthritis 
In 2008–09, 12% of the health-care expenditure for rheumatoid arthritis ($44 million) was 
attributable to hospital admitted patient services (Table C3, Appendix C). This is because 
most of the treatment for rheumatoid arthritis is conducted in non-admitted patient settings 
such as hospital outpatient clinics and a range of other specialist and allied health services 
that patients receive without being formally admitted to hospital. People with rheumatoid 
arthritis may receive hospital care when their symptoms cannot be managed by medications 
and primary care interventions. According to the NHMD, in 2008–09, there were 9,000 
hospitalisations with a principal diagnosis of rheumatoid arthritis. 
In 2008–09, out-of-hospital medical expenses accounted for 10% ($37 million) of expenditure 
on rheumatoid arthritis. This is likely to underestimate the full expenditure in this area given 
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data gaps. In particular, Australian guidelines recommend treatment and management of 
rheumatoid arthritis by health-care professionals working within multidisciplinary teams, 
such as rheumatologists, physiotherapists, nurses, occupational therapists, podiatrists, 
dietitians, psychologists, pharmacists and community health workers (RACGP 2009a). 
Limited information is available on the activity or expenditure associated with much of this 
activity.  
The majority of expenditure on rheumatoid arthritis is for prescription pharmaceuticals 
($275 million, accounting for 77% of the health-care expenditure in 2008–09). While a large 
proportion of this expenditure is likely to be on bDMARDS, these medications are prescribed 
only by specialists and are not separately identified in the AIHW Disease Expenditure 
Database (where they are grouped under a broader category of ‘anti-inflammatory and anti-
rheumatic products’ based on GP-prescribing behaviour). Based on raw PBS/RPBS data, in 
2008–09, approximately 79,000 units of bDMARDs were dispensed and almost $143 million 
in benefits were paid (AIHW 2013). 
Osteoporosis 
Health-care expenditure for hospital admitted patient services accounted for a small 
proportion (14%) of the total expenditure on osteoporosis ($44 million) in 2008–09 (Table C3, 
Appendix C). Services provided by hospitals are not commonly sought for treating and 
managing osteoporosis itself, although its consequences, such as hip fractures, often are.  
Expenditure for hospital admitted patient services for osteoporosis presented here is likely to 
be a substantial underestimate. This is because hospital expenditure in the AIHW Disease 
Expenditure Database is allocated on the basis of principal diagnosis only and therefore 
excludes the broader group of hospitalised fractures (including minimal trauma fractures). 
According to the NHMD, in 2008–09 there were 65,821 ‘osteoporosis-related’ hospitalisations 
for persons aged 50 and over. Of these, 6,732 hospitalisations were for a principal diagnosis 
of osteoporosis (therefore captured here) and 59,089 for a principal diagnosis of minimal 
trauma fracture. It is not possible to confirm if all the 59,089 hospitalisations were among 
people with osteoporosis. There is some evidence that many of these fractures would have 
occurred in people without osteoporosis (Nguyen et al. 2007). However, it is possible that the 
hospitalisation expenditure estimates presented here reflect as few as 10% of all 
osteoporosis-related hospitalisations. 
Out-of-hospital medical expenses accounted for 22% ($68 million) of health-care expenditure 
on osteoporosis in 2008–09. This is likely to be a marked underestimate because it does not 
capture the use of community-based medical specialists (such as orthopaedic surgeons and 
endocrinologists) and allied health services (such as physiotherapy and occupational 
therapy) following hip fractures. 
In 2008–09, the majority (63%) of health-care expenditure for osteoporosis was for 
prescription pharmaceuticals. Pharmaceutical medicines are normally used in managing 
osteoporosis to increase bone mineral density (for example, anti-resorptive medications 
known as bisphosphonates), to manage symptoms such as pain and inflammation, and to 
reduce the risk of fractures. While we do not have precise estimates of the expenditure on 
most of these types of pharmaceuticals, it is known, based on PBS/RPBS data, that in  
2008–09, approximately 1,500,000 units of bisphosphonates (alendronate and risedronate) 
were dispensed and almost $63 million in benefits paid (Department of Human Services 
2013).  
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5 How does expenditure vary by age and 
sex? 
In 2008–09, total allocated health-care expenditure on arthritis and other musculoskeletal 
conditions was relatively low in younger age groups. It became progressively higher with 
each older age group from the age of 35, lowering in those aged 75 and over (Figure 5.1). 
Expenditure on arthritis and musculoskeletal conditions was higher for females 
($3,245 million or 57% of total expenditure) than for males ($2,444 million or 43%), largely 
reflecting the higher prevalence of arthritis among females (54%) than males (46% males) 
(ABS 2012).  
 
 
Source: Disease Expenditure Database, AIHW. 
Figure 5.1: Expenditure on arthritis and other musculoskeletal conditions, by age and sex, 2008–09 
($ million) 
Overall expenditure was higher for females than males for all groups of musculoskeletal 
conditions shown in Figure 5.2, but the collective group ‘other’ musculoskeletal conditions 
could mask variations in individual diseases. The greatest disparity was noted for 
expenditure on osteoporosis: expenditure for females was 5 times as high as that for males 
($257 million for females and $49 million for males). This aligns reasonably closely with the 
self-reported prevalence of osteoporosis for females (81%), which is more than 4 times as 
high as that for males (19%) (ABS 2012). Results based on bone mineral testing show similar 
sex differences, with one study finding that rates were nearly 4 times as high in females as in 
males aged 50 or over (23% of females and 6% of males) and about 3 times as high in females 
as in males aged 70 and over (43% of females and 13% of males) (Henry et al. 2011).  
Prevalence alone does not account for the full 5-fold difference in uptake of pharmaceuticals; 
it may also be affected by other factors such as consumer awareness and doctor-diagnosing 
practices. For example, use of bisphosphonates is recognised as one of a range of treatments 
for post-menopausal women in terms of preventing fracture and improving quality of life 
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(Christenson et al. 2012). It is also noted that, despite high-level evidence for efficacy, safety 
and effectiveness, fewer Australian males with osteoporosis take specific osteoporosis 
targeted treatment (RACGP 2010). Per person expenditure across all arthritis and other 
musculoskeletal conditions was also higher for females ($301 per person) than males ($229 
per person) and highest for people aged 75–84 ($1,007 per person) (Table C12, Appendix C). 
 
 
Source: Disease Expenditure Database, AIHW. 
Figure 5.2: Expenditure on specific types of arthritis and other musculoskeletal conditions, by sex, 
2008–09 ($ million) 
The greatest difference in the overall health-care expenditure for arthritis and other 
musculoskeletal conditions between the sexes was for prescription pharmaceuticals, where 
more than twice as much was spent on females ($635 million) than on males ($286 million). 
Expenditure on out-of-hospital medical expenses and admitted patient services was 41% and 
12% higher, respectively, for females than for males (Figure 5.3) (Table C6, Appendix C).  
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Source: Disease Expenditure Database, AIHW. 
Figure 5.3: Expenditure on arthritis and other musculoskeletal conditions, by health-care sectors 
and sex, 2008–09 ($ million) 
Osteoarthritis 
There was more expenditure on females than males with osteoarthritis, as would be expected 
given the higher prevalence of the condition in females (66% in females and 34% in males). In 
2008–09, $931 million (57% of the estimated expenditure allocated to osteoarthritis) was 
spent overall on females compared with $706 million (43%) on males. The expenditure on 
males is high relative to their overall prevalence (that is, 43% of expenditure compared with 
34% prevalence) which may suggest males with osteoarthritis are more likely to receive more 
costly procedures such as joint replacement surgery. There is some evidence that physicians 
were more likely to recommend total knee replacement for male patients with osteoarthritis 
than female patients (Borkhoff et al. 2008). However, females were, overall, more likely to 
undergo a joint replacement procedure for osteoarthritis given their higher prevalence of this 
condition, although there are some age groups and joint replacement types for which males 
have a higher rate (AIHW 2014b).  
Osteoarthritis is a condition that predominantly affects people aged 45 and over. Hence, it is 
not surprising that this is where most of the expenditure occurred ($1,587 million or 97%). 
Expenditure was highest in the 65–74 age group ($538 million) (Table C7, Appendix C).  
Per person expenditure for osteoarthritis was also higher for females than males and highest 
in the elderly aged 75–84 ($414) (Table C12, Appendix C). For both sexes, per person 
expenditure became progressively higher with each older age group up to age 84 ($414), 
lowering in those aged 85 or over ($219). This is most likely because, as this condition 
progresses, interventions become progressively more costly and likely to involve 
hospitalisation.  
More was spent on females than males with osteoarthritis across each health-care sector 
(Figure 5.4). 
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Source: Disease Expenditure Database, AIHW. 
Figure 5.4: Expenditure on osteoarthritis, by health-care sectors and sex, 2008–09 ($ million) 
Back problems 
The total allocated health-care expenditure on back problems for females was 1.2 times that 
for males (that is 20% more was spent on females than males). Per person expenditure was 
progressively higher with each age group through to the age group 55–64 ($236 million), 
before declining with each subsequent age group to $57 million for those aged 85 or over 
(Table C8, Appendix C).  
Per person expenditure on back problems was $55 in 2008–09. More was spent on females on 
average ($60 per person) than on males ($50), with more spent on females for all age groups 
above 0–4 (Table C12, Appendix C). Although overall spending on the most elderly age 
groups was lower than for some younger age groups, people aged 75–84 had the highest 
estimated per person expenditure (Table C12, Appendix C). More was spent on females than 
males across each health-care sector (Figure 5.5; Table C8, Appendix C). 
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Source: Disease Expenditure Database, AIHW. 
Figure 5.5: Expenditure on back problems, by health-care sectors and sex, 2008–09 ($ million) 
Rheumatoid arthritis 
The total allocated health-care expenditure for rheumatoid arthritis was higher for females 
($250 million or 70%) than males ($105 million or 30%) (Table C9, Appendix C), as would be 
expected given the higher prevalence of rheumatoid arthritis in females (64% for females 
versus 36% for males) (ABS 2012). The highest expenditure for females was for those aged 
65–74 ($76 million), and for males those aged 55–64 ($34 million). 
Expenditure per person was higher from the 45–54 age group upward, especially in females. 
This trend corresponds with age groups commonly associated with the onset of the disease 
and the fact that females tend to develop rheumatoid arthritis more often and earlier than 
males (ABS 2012). The greatest amount was spent on females aged 65–74 ($98 million) and 
males aged 55–64 ($29 million) (Table C12, Appendix C). 
More was spent on females than males with rheumatoid arthritis across each health-care 
sector. This was especially true for prescription pharmaceuticals, where over twice as much 
($192 million) was spent on females than on males ($82 million). Expenditure on admitted 
patient services and out-of-hospital expenses for females was almost twice as high as for 
males (Figure 5.6; Table C9, Appendix C). 
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Source: Disease Expenditure Database, AIHW. 
Figure 5.6: Expenditure on rheumatoid arthritis, by health-care sectors and sex, 2008–09 ($ million) 
Osteoporosis 
In 2008–09, total allocated expenditure for osteoporosis was $49 million for males and 
$257 million for females (Table C10, Appendix C). Expenditure in each age group was 
progressively higher, more so for females than males, showing a similar pattern to that for 
rheumatoid arthritis. While less expenditure was reported for those aged 85 or over, 
expenditure for females ($39 million) was almost 5 times that for males ($8 million) in this 
age group.  
Expenditure per person by age and sex showed a slightly different pattern, although more 
was spent on females ($24 per person) than on males ($5). Per person expenditure was 
highest in females aged 75–84 ($168) and males aged 85 or over ($65) (Table C12, 
Appendix C). 
Most of the difference in expenditure for osteoporosis between males and females is related 
to prescription pharmaceuticals (Figure 5.7). In 2008–09, the amount spent on prescription 
pharmaceuticals for females with osteoporosis was over 5 times as high as that spent for 
males ($165 million and $29 million, respectively). Expenditure on hospital admitted patient 
services was 4 times as high, and out-of-hospital expenses 5 times as high, for females than 
for males (Table C10, Appendix C). 
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Source: Disease Expenditure Database, AIHW. 
Figure 5.7: Expenditure on osteoporosis, by health-care sectors and sex, 2008–09 ($ million) 
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6 Are expenditure patterns changing over 
time? 
This chapter describes changes in the patterns of health-care expenditure between 2000–01, 
2004–05 and 2008–09, adjusting for inflation—that is, using constant prices. 
From 2000–01 to 2008–09, total health system expenditure on arthritis and other 
musculoskeletal conditions increased by 67% from $3,411 million to $5,690 million (constant 
prices) (Table C13, Appendix C). This compares with a total increase of 52% for all chronic 
diseases—from $42,915 million in 2000–01 to $65,129 million in 2008–09. Over the same 
period, total health-care expenditure for arthritis and other musculoskeletal conditions 
remained at about 9% of total allocated expenditure for all diseases (Table C13, Appendix C).  
Expenditure on hospital admitted patient services was the dominant component of 
expenditure at all three time points, increasing from $1,673 million in 2000–01, to 
$2,316 million in 2004–05 and to $3, 091 million in 2008–09 (Figure 6.1). 
Out-of-hospital expenses also increased steadily across the three time points from 
$1,264 million in 2000–01, to $1,341 million in 2004–05 and to $1,677 million in 2008–09. 
Expenditure on prescription pharmaceuticals was the lowest component in all three years, 
with a steady increase in expenditure—from $475 million in 2000–01, to $687 million in  
2004–05 and to $922 million in 2008–09. 
 
 Source: Disease Expenditure Database, AIHW. 
Figure 6.1: Total health-care expenditure on arthritis and other musculoskeletal conditions, 
Australia, 2000–01, 2004–05 and 2008–09 ($ million) 
Further examination of time series trends is not currently possible due to data limitations, 
particularly in relation to out-of-hospital and pharmaceutical expenses (see Chapter 2 for 
details).  
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7 Discussion 
Arthritis and other musculoskeletal conditions (such as back problems, osteoporosis and 
many other conditions) are a major cause of pain and disability, placing a high economic and 
personal burden on the community. 
In 2008-09, estimated health-care expenditure allocated to arthritis and other musculoskeletal 
conditions in Australia totalled $5,690 million; it was the fourth most expensive disease 
group, accounting for 8.7% of total health-care expenditure allocated to disease groups 
($65,129 million). Osteoarthritis accounted for 29% of the estimated health-care expenditure, 
back problems 21%, rheumatoid arthritis 6%, and osteoporosis 5%. ‘Other’ musculoskeletal 
conditions (a large group of conditions) accounted for 39% of the total expenditure. 
Health-care expenditure by health-care sector 
Estimated health-care expenditure on hospital admitted patients accounted for the highest 
proportion of expenditure on arthritis and other musculoskeletal conditions (54% or 
$3,091 million), followed by out-of-hospital medical expenses (30% or $1,677 million) and 
prescription pharmaceuticals (16% or $922 million). 
The pattern of expenditure across health-care sectors varied markedly across the various 
musculoskeletal conditions. For example, the majority of estimated expenditure for 
rheumatoid arthritis and osteoporosis was on pharmaceuticals (77% and 63%, respectively) 
and the largest proportion of osteoarthritis-related expenditure was on admitted patient 
hospital services (77%).  
Health-care expenditure by various musculoskeletal 
conditions 
The patterns of expenditure across health-care sectors largely reflect what is known about 
the different impacts of these musculoskeletal conditions and the interventions undertaken 
to prevent, diagnose, treat and manage them. For example, the relatively high expenditure 
on admitted patient hospital services for osteoarthritis relates largely to the use of joint 
replacement and other forms of surgery (for example, arthroscopy) in its management.  
In contrast, the relative dominance of expenditure on prescription pharmaceuticals for 
rheumatoid arthritis and osteoporosis relates to the availability of anti-inflammatory/ 
anti-rheumatic and anti-resorptive drugs, respectively. The relative dominance of 
expenditure on prescription pharmaceuticals for rheumatoid arthritis is even more notable 
given that it represents an underestimate of the full expenditure in this area.  
Expenditure on bDMARDs is not separately or comprehensively captured in the estimates 
presented here (because they are prescribed exclusively by medical specialists and the data 
presented here are modelled based on GP-prescribing practices). It is known that 
expenditure on these medications accounted for $143 million in benefits paid through the 
PBS and RPBS in 2008–09.  
The relatively small level of hospital expenditure for osteoporosis are also affected by the 
relatively narrow definition of osteoporosis-related hospitalisations used here, which focuses 
only on hospitalisations with a principal diagnosis of osteoporosis. Expenditure for a 
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proportion of the much larger group of hospitalisations for minimal trauma fractures may 
also have been related to osteoporosis. However, quantifying this proportion accurately is 
currently challenging. 
Health-care expenditure by sex and age  
Total allocated health-care expenditure for musculoskeletal conditions is greater for females 
($3,245 million overall and $301 per female) than males ($2,444 million overall and $229 per 
male), with sex differences for specific musculoskeletal grouping reflecting known 
differences in the age of onset and prevalence for females and males. There is lower than 
expected expenditure on osteoporosis pharmaceutical treatments, such as bisphosphonates, 
for males relative to females, given the prevalence of this condition in men and women.  
Overall estimated expenditure for arthritis and other musculoskeletal conditions was higher 
in the older age groups, increasing with age from $172 million for children aged 0–14 to 
$494 million for people aged 35–44 and $1,245 million for those aged 65–74. It then tapered 
off for people aged 75 or over. This is broadly consistent with prevalence estimates of these 
conditions (AIHW 2014b), and also with the likelihood that, as these conditions progress, 
treatment options move toward the more expensive end of the management continuum, 
including hospitalisation. 
Comparisons with other health-care expenditure 
estimates 
The results presented in this report are considerably lower than the findings of two recent 
studies conducted in Australia, which look at a much broader concept of the economic 
implications of arthritis and other musculoskeletal conditions on individuals, families and 
society. One study, conducted by Arthritis and Osteoporosis Victoria (2013), estimated the 
total cost of arthritis and other musculoskeletal conditions in Australia to be $55,063 million 
in 2012. Of this total cost, $20,868 million was the overall financial cost (which includes 
health costs and productivity costs); another $34,194 million was the burden of disease cost.  
Another study, conducted by Osteoporosis Australia, estimated the direct and indirect cost 
of osteoporosis/osteopenia in Australia in 2012 to be $2,754 million (Watts et al. 2013). Of the 
overall costs, $2,589 million are direct costs and $165 million included costs from 
productivity losses associated with fractures due to hospitalisation (acute and rehabilitation). 
The estimates are not comparable with those presented here for a number of reasons. In 
addition to direct health-care costs, the above-mentioned studies included detailed estimates 
of non-direct health-care costs such as productivity costs (for example, reduced employment, 
lost superannuation, presenteeism (attending work while sick), absenteeism and premature 
death), carer costs, community non-health services costs (such as home help, Meals on 
Wheels) and informal community care costs. The estimates are also based on a different time 
period to that presented here. In relation to the Osteoporosis Australia study, a much 
broader group of fractures (both those requiring hospitalisation and other fractures) was also 
used in estimating the costs of osteoporosis. 
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Conclusion 
Arthritis and other musculoskeletal conditions generate substantial health-care costs in 
Australia. Although the estimates presented here have some limitations, they provide 
valuable information about how the levels of expenditure on musculoskeletal conditions 
compare with expenditure on other health conditions and how they are distributed across 
different health care sectors, age and sex groups. The estimates also highlight how these 
broad patterns of expenditure have varied over time.  
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Appendix A: Data sources 
AIHW Disease Expenditure Database 
The Disease Expenditure Database contains estimates of health-care expenditure by disease 
category, age group and sex for admitted patient hospital services, out-of-hospital medical 
expenses and prescription pharmaceuticals (details are provided in Chapter 2). Also see the 
data quality statement at Appendix B. 
2011–12 ABS National Health Survey  
The 2011–12 ABS NHS is part of the broader 2011–13 ABS Australian Health Survey that 
includes a nationally representative sample of 35,000 people from the general population as 
well as a specific survey of 13,250 Aboriginal and Torres Strait Islander people. The content 
of the Australian Health Survey covers topics such as nutrition, physical activity, and 
biomedical measures (the National Nutrition and Physical Activity Survey and the National 
Health Measures Survey).  
Previous NHS surveys were conducted in 2007–08, 2004–05, 2001, 1995, 1989–90, 1983 and 
1977. The survey is community based and does not include information from people living in 
nursing homes or otherwise institutionalised.  
Data available from the NHS include self-reports of various forms of arthritis, disc disorders, 
sciatica, back pain/problems not elsewhere classified, osteoporosis and other diseases of the 
musculoskeletal system and connective tissues. The survey also collects information about 
health services and medicine use, as well as any other health-related action taken to manage 
these conditions.  
In this report, data from the 2011–12 NHS have been used to provide information on the 
prevalence of arthritis and other musculoskeletal conditions in the Australian population, 
psychological distress, and self-assessed health status. 
While the NHS provides a vast array of nationally-representative data, some limitations need 
to be considered; namely, the self-reported sourcing of some data, and the cross-sectional 
nature of the survey. 
The analysis in this report relies upon the quality of the data available. Much of the data 
collected by the NHS are self-reported by respondents and, therefore rely heavily on the 
respondents’ knowing and providing accurate information. In some cases, the survey relies 
on the respondents’ ability to recall their behaviours, such as physical activity or alcohol 
consumed in the week before the interview. The NHS is designed to prompt respondents so 
that the most accurate information is collected, but there may be reasons why the 
information may be compromised. 
More information on the data quality of this survey can be found in the following 
ABS publications: Australian Health Survey: user’s guide 2011–13 
<http://www.abs.gov.au/ausstats/abs@.nsf/mf/4363.0.55.001>. 
AIHW National Hospital Morbidity Database 
The NHMD is a compilation of episode-level records from admitted patient morbidity data 
collection systems in Australian hospitals. 
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The data supplied are based on the National Minimum Data Sets (NMDSs) for Admitted 
patient care and include demographic, administrative and length of stay data, as well as data 
on the diagnoses of the patients, the procedures they underwent in hospital and external 
causes of injury and poisoning. 
The purpose of the NMDS for Admitted patient care is to collect information about care 
provided to admitted patients in Australian hospitals. The scope of the NMDS is episodes of 
care for admitted patients in all public and private acute and psychiatric hospitals, 
free-standing day hospital facilities and alcohol and drug treatment centres in Australia. 
Hospitals operated by the Australian Defence Force or corrections authorities and in 
Australia‘s off-shore territories are not in scope, but some are included. 
The reference period for this data set is 2011–12. The data set includes records for admitted 
patient separations between 1 July 2011 and 30 June 2012. 
The data quality statement for this 2011–12 NHMD is at the following web site: 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/529483>. 
Metadata information for the NMDSs that are the basis for the AIHW National Hospital 
Morbidity Databases is published in the AIHW’s online metadata repository—METeOR—
and the National Health Data Dictionary. METeOR and the National Health Data Dictionary 
can be accessed, respectively, via the following AIHW websites: 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/181162> 
<http://www.aihw.gov.au/publication-detail/?id=6442468385>. 
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Table A1: Codes used in identifying total joint replacement and arthroscopic procedures of the 
knee for people with a principal diagnosis of osteoarthritis 
Procedure Codes 
Total joint replacement  
Primary total knee replacement 4951800, 4951900, 4952100, 4952101, 
4952102, 4952103, 4952400, 4952401, 
4953401 
 
Primary total hip replacement 4931800, 4931900 
 
Arthroscopic procedures of the knee 
Patellofemoral stabilisation 4950301 
Osteoplasty of knee 4950305 
Arthroscopic reconstruction of knee 4953900 
Arthroscopy of knee 4955700 
Arthroscopic biopsy of knee 4955701 
Arthroscopic excision of meniscal margin or plica of knee 4955702 
Arthroscopic debridement of knee 4955800 
Arthroscopic chondroplasty of knee 4955801 
Arthroscopic osteoplasty of knee 4955802 
Arthroscopic chondroplasty knee with multiple drilling or implant 4955900 
Arthroscopic removal of loose body, knee 4956000 
Arthroscopic trimming ligament of knee 4956001 
Arthroscopic lateral release of knee 4956002 
Arthroscopic meniscectomy of knee 4956003 
Arthroscopic lateral release of knee with debridement, osteoplasty or 
chondroplasty 4956100 
Arthroscopic meniscectomy of knee with debridement, osteoplasty or 
chondroplasty 4956101 
Arthroscopic lateral release of knee with chondroplasty and multiple drilling 
or implant 4956200 
Arthroscopic meniscectomy of knee with chondroplasty and multiple drilling 
or implant 4956201 
Arthroscopic removal of loose body, knee with chondroplasty and multiple 
drilling or implant 4956202 
Arthroscopic repair of meniscus of knee 4956300 
Arthroscopic synovectomy of knee 4956600 
Sources: Bohensky et al. 2012; AIHW 2008. 
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Appendix B: Data quality statement 
Disease expenditure database 2008–09 
Summary of key data quality issues 
• The Disease Expenditure Database contains estimates of expenditure by disease 
category, age group and sex for each of the following areas of expenditure: admitted 
patient hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services and public health 
cancer screening.  
• Estimates are derived from combining information from the NHMD, the NPHED, the 
Health Expenditure Database, the NHCDC and the BEACH survey.  
• The database contains a conservative estimate of total expenditure and equates to 
around 70% of total recurrent health expenditure.  
Description 
The estimates of expenditure in the Disease Expenditure Database are as explained above. 
Definitions for admitted patient hospital services, out of-hospital medical services and 
prescription pharmaceuticals are as follows: 
• Admitted patient hospital costs refer to the cost of services for admitted patients in both 
public and private acute hospitals and psychiatric hospitals, as well as expenditure on 
medical services provided to private admitted patients in hospitals. 
• Out-of-hospital medical expenses refer to the cost for services provided by, or on behalf 
of, registered medical practitioners who are funded by the MBS, Department of 
Veterans’ Affairs, compulsory motor vehicle third-party insurance, workers’ 
compensation insurance, private health insurance funds, Australian Government 
premium rebates allocated to medical services, MBS co-payments and other  
out-of-pocket payments. They also include non-MBS medical services (such as the 
provision of vaccines for overseas travel) as well as some expenditure by the Australian 
Government under funding arrangements that are alternatives to the fees for service. 
They exclude medical services provided to public admitted patients in public hospitals 
and medical services provided to public patients at outpatient clinics in public hospitals. 
Also excluded are the costs for medical services provided to private admitted patients in 
hospitals, which are counted as part of admitted patient costs.  
• Prescription pharmaceuticals refer to the cost of pharmaceuticals listed in the schedule 
of the pharmaceuticals under the PBS and the RPBS for which pharmaceutical benefits 
have been paid or are payable. Also included are the costs for under co-payment 
prescriptions and private prescriptions. Under co-payment prescriptions are those 
pharmaceuticals listed in the PBS or RPBS, the total costs of which are equal to or less 
than the statutory patient contribution for the class of patient concerned, while private 
prescriptions are those pharmaceuticals dispensed through private prescriptions that do 
not fulfil the criteria for payment or benefit under the PBS or RPBS. 
Estimates are derived from combining information from the NHMD, the NPHED, the 
NHCDC and the Health Expenditure Database.  
Proportions derived from the BEACH survey relating to 2007 to 2009 are also used in 
compiling the estimates for out-of-hospital medical services and prescription 
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pharmaceuticals. The BEACH data were collected by the Family Medicine Research Centre 
of the University of Sydney in collaboration with the AIHW.  
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that was not able to be allocated by disease includes capital expenditure as well 
as expenditure for non-admitted patient hospital services, over-the-counter drugs, other 
health practitioner services (except optometry), community health services expenditure 
(except community mental health), expenditure on public health programs (except cancer 
screening programs), health administration, health aids and appliances, and patient 
transport (ambulance). 
Institutional environment 
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 (Cwlth) to provide reliable, regular and 
relevant information and statistics on Australia’s health and welfare. It is an independent 
statutory authority established in 1987, governed by a management board, and accountable 
to the Australian Parliament through the Health and Ageing portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the AIHW’s main functions is to work with the states and territories to improve the 
quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these data sets and disseminate information and 
statistics. 
Compliance with both the AIHW Act and the Privacy Act 1988 (Cwlth) ensures that the data 
collections managed by the AIHW are kept securely and under the strictest conditions with 
respect to privacy and confidentiality. 
For further information, see the AIHW website <http://www.aihw.gov.au/>. 
The BEACH survey data for 2007–08 and 2008–09 were collected by the Family Medicine 
Research Centre of the University of Sydney in collaboration with the AIHW. Data for the 
Disease Expenditure Database were derived from data from the NHMD, NPHED and Health 
Expenditure Database as well as survey-based data. 
Timeliness 
The reference period for this data set is 2008–09. The Disease Expenditure Database can be 
updated only once the NHMD, NPHED, NHCDC and Health Expenditure Databases have 
all been updated for the relevant financial year, which is currently a minimum of 15 months 
after the end of the financial year. 
The AIHW first published 2008–09 data from the Disease Expenditure Database in Australia’s 
health 2012 in June 2012. 
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Accessibility 
The AIHW provides a variety of products that draw upon the Disease Expenditure Database 
2008–09. Published products currently available on the AIHW website include: 
• Australia’s health 2012  
• Dementia in Australia  
• Incontinence in Australia: prevalence, experience and cost. 
Users can request data not available online or in reports via the Expenditure and Economics 
Unit on (02) 6244 1119 or via email to <expenditure@aihw.gov.au>. Requests that take longer 
than half an hour to compile are charged for on a cost-recovery basis. 
Interpretability 
Supporting information on the quality and use of the Disease Expenditure Database are 
published in Health system expenditure on disease and injury in Australia, 2004–05 (technical 
notes).  
Most important to note is that the Disease Expenditure Database estimates: 
• are a conservative estimate based on around 70% of total recurrent health expenditure  
• are only one measure of the size of the disease burden on the community (that is, the 
‘size of the problem’)  
• are not the same as loss of health due to disease  
• should not be regarded as how much would be saved if a specific disease or all diseases 
were prevented 
• are not an estimate of the total economic impact of diseases in the Australian 
community. This is because the estimates do not include costs that are not accrued by 
the health system, such as travel costs of patients, costs associated with the social and 
economic burden on carers and family, and costs incurred due to lost quality and 
quantity of life. 
Relevance 
Disease expenditure estimates provide a broad picture of the use of health system resources 
classified by disease group, as well as a reference source for planners and researchers 
interested in costs and use patterns for particular disease groups.  
The Disease Expenditure Database contains a conservative estimate based on around 70% of 
total recurrent health expenditure. 
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure that could not be allocated by disease includes capital expenditure as well as 
expenditure for non-admitted patient hospital services, over-the-counter drugs, other health 
practitioner services (except optometry), community health services expenditure (except 
community mental health), expenditure on public health programs (except cancer screening 
programs), health administration, health aids and appliances, and patient transport 
(ambulance). 
Readers need to bear in mind that cost-of-illness data provide only estimates of the impact of 
a disease on health system expenditures. The estimates of the cost of treating and/or 
preventing a disease cannot be used to indicate the loss of health due to that disease.  
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Care should be taken not to interpret expenditure associated with disease treatment as 
simply an estimate of the savings that would result from prevention of disease. Conversion 
of the opportunity cost—or the benefits forgone—of resources being devoted to disease 
treatment into expenditure savings involves a number of additional considerations. See, for 
example, AIHW: Mathers et al. 1998. 
Accuracy 
Apart from hospital admitted patient services data, the method for estimating disease 
expenditure is generally a ‘top-down’ approach, where total expenditure across the health 
system is estimated and then allocated to the relevant conditions. This method yields 
consistency, good coverage, and totals that add up to known expenditures. However, it is 
not as sensitive or accurate for any specific disease as a detailed ‘bottom-up’ analysis of 
actual costs incurred by patients with that disease. In most cases, a bottom-up analysis is not 
possible due to a lack of available data. 
Both out-of-hospital medical services and prescription pharmaceuticals expenditure 
estimates draw upon proportions derived from BEACH surveys for 2007 to 2009. In each 
BEACH survey, the vocationally registered GPs and all general practice registrars who 
claimed a minimum of 375 general practice A1 Medicare items in the most recently available 
3 months make up the population from which a sample is drawn (Britt et al. 2009). GPs are 
randomly selected from this population and approached for participation in the survey. Each 
BEACH survey includes a sample of 1,000 recognised practising GPs across the country 
(about 6% of all recognised practising GPs) completing details for 100 consecutive GP 
encounters. Each BEACH survey contains details of about 100,000 encounters between GPs 
and patients (about a 0.1% sample of all general practice encounters) (Britt et al. 2009). For 
further information regarding data collection methods in BEACH surveys, refer to the 
General practice activity in Australia 2008–09 report (Britt et al. 2009). In light of these sampling 
methods used, time series comparisons of expenditure estimates for out-of-hospital medical 
services and prescription pharmaceuticals need to be treated with caution. Refer to the data 
quality statements for the NHMD, NPHED and the Health Expenditure Database for further 
information on the accuracy of the data within these databases. 
Coherence 
To ensure consistency between the Disease Expenditure Database and associated burden of 
disease projects, the disease groups used in the 2008–09 disease expenditure estimates were 
based on the 176 diseases that were published in the Australian burden of disease studies 
(AIHW: Mathers et al. 1999; Begg et al. 2007). Extra categories were added to provide a more 
comprehensive list of diseases and the two categories ‘Symptoms, signs and ill-defined 
conditions’ and ‘Other contact with health services’ were included to cover some health 
service expenditures that cannot be allocated by disease.  
The methodologies used to estimate expenditures for admitted patient hospital services have 
remained unchanged between 2004–05 and 2008–09. Hence, time series comparisons for 
admitted patient hospital services are possible.  
While the methodologies used to estimate expenditures for out-of-hospital medical services 
and prescription pharmaceuticals have also remained unchanged between 2004–05 and 
2008–09, the use of data based on the BEACH survey in the methodologies has meant that 
time series comparisons for these areas of expenditure should be made with caution. 
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Comparisons over time for optometrical and dental services, community mental health 
services and public health cancer screening can be made with more confidence. 
Implementation date 
6 February 2012. 
Link to the data quality statement 
The data quality statement for the Disease Expenditure Database 2008–09 is at: 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/512599>. 
Source and reference attributes 
AIHW (Australian Institute of Health and Welfare): Mathers et al. 1998. Disease costing 
methodology used in the disease costs and impact study 1993–94. Cat. no. HWE 7. Canberra: 
AIHW. 
AIHW: Mathers C et al. 1999. The burden of disease and injury in Australia. Cat. no. 
PHW 17. Canberra: AIHW. 
Begg S, Vos T, Barker B, Stevenson C, Stanley L & Lopez AD 2007. The burden of disease and 
injury in Australia 2003. AIHW cat. no. PHE 82. Canberra: AIHW. 
Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y et al. 2009. General practice 
activity in Australia 2008–09. General practice series no. 25. Cat. no. GEP 25. Canberra: 
AIHW. 
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Appendix C: Detailed statistical tables 
Table C1: Prevalence of arthritis and other musculoskeletal conditions, by age group, 2011–12 
 Osteoarthritis Rheumatoid arthritis Back problems Osteoporosis 
Age group 
(years) 
No. (’000) % No. (’000) % No. (’000) % No. (’000) % 
0–15 n.p. 0.0 5.8 0.1* 39.0 0.9 n.p 0.0 
16–34 47.2 0.8 23.1 0.4** 602.5 10.1 13.7 0.2** 
35–64 898.1 10.3 243.7 2.8 1,730.7 19.8 289.3 3.3 
65–79 642.1 28.8 127.5 5.7 511.6 23.0 273.2 12.3 
80 or over 242.0 34.9 40.1 5.8 118.4 17.1 147.3 21.2 
All ages 1,821.5 8.0 444.9 1.9 3,003.8 13.2 728.2 3.1 
n.p. Not publishable because of small numbers and very high relative standard errors. 
* Estimate is subject to sampling variability too high for practical purposes (relative standard error greater than 50%). 
** Estimate is subject to high standard errors (relative standard error of 25–50%) and should be used with caution. 
Notes  
1.  Cells in this table have been randomly adjusted to avoid the release of confidential data. Discrepancies may occur between sums of the 
component items and totals. 
2. See Figure 1.1. 
3. Prevalence for all ages was age-standardised to Australian population as at 30 June 2001. 
Source: ABS Australian Health Survey 2011–12. 
Table C2: Expenditure by type of arthritis and other  
musculoskeletal conditions, 2008–09 ($ million) 
Condition $m % 
Osteoarthritis 1,637 28.8 
Rheumatoid arthritis 355 6.2 
Back problems 1,177 20.7 
Osteoporosis 306 5.4 
Other  2,214 38.9 
Total musculoskeletal 
conditions 5,690 100.0 
Note: See Figure 3.2. 
Source: Disease Expenditure Database, AIHW. 
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Table C3: Distribution of expenditure for arthritis and other musculoskeletal conditions, by 
health-care sectors, 2008–09 ($ million) 
Health-care 
sector 
Osteoarthritis Rheumatoid 
arthritis 
Back problems Osteoporosis Other 
musculoskeletal 
conditions 
$m % $m % $m % $m % $m % 
Hospital admitted 
patient services 1,256 76.7 44 12.4 560 47.6 44 14.4 1,188 53.6 
Out-of-hospital 
medical expenses 282 17.2 37 10.4 464 39.4 68 22.2 825 37.3 
Prescription 
pharmaceuticals 99 6.0 274 77.2 153 13.0 194 63.4 201 9.1 
Total 
expenditure 1,637 100.0 355 100.0 1,177 100.0 306 100.0 2,214 100.0 
Note: See Figure 4.1. 
Source: Disease Expenditure Database, AIHW. 
Table C4: Expenditure on arthritis and other musculoskeletal conditions,  
by age and sex, 2008–09 ($ million) 
Age group (years) 
Males Females Persons 
$m 
0–4 13 60 72 
5–14 48 51 100 
15–24 105 86 190 
25–34 139 119 258 
35–44 250 244 494 
45–54 391 457 88 
55–64 551 687 1,238 
65–74 509 736 1,245 
75–84 361 617 978 
85+ 78 188 266 
All ages 2,444 3,245 5,690 
 Note: See Figure 5.1. 
Source: Disease Expenditure Database, AIHW. 
Table C5: Expenditure on specific types of arthritis and other musculoskeletal 
conditions, by sex, 2008–09 ($ million) 
Condition 
Males Females Persons 
$m 
Osteoarthritis 706 931 1,637 
Rheumatoid arthritis 105 250 355 
Back problems 536 642 1,177 
Osteoporosis 49 257 306 
Other musculoskeletal 
conditions 1,048 1,165 2,214 
All musculoskeletal 
conditions 2,444 3,245 5,690 
Components may not sum to the total due to rounding. 
Note: See Figure 5.2. 
Source: Disease Expenditure Database, AIHW. 
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Table C6: Expenditure for arthritis and other musculoskeletal conditions, by health-care sectors, 
age and sex, 2008–09 ($m)($ million) 
Age 
group 
(years) 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
males 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines 
Total 
females 
Total 
persons 
Males Females  
0–4 8.9 2.2 1.6 12.7 7.6 7.2 44.9 59.7 72.4 
5–14 31.0 16.7 0.8 48.5 33.7 12.7 4.8 51.2 99.7 
15–24 69.8 30.6 4.2 104.5 46.3 35.7 3.6 85.6 190.2 
25–34 85.8 45.4 7.4 138.6 53.1 52.1 14.3 119.5 258.1 
35–44 135.8 91.7 22.7 250.2 100.5 113.1 30.3 243.9 494.0 
45–54 203.3 125.2 62.6 391.2 190.2 181.3 85.8 457.2 848.5 
55–64 316.7 155.9 78.3 550.9 340.4 228.8 118.1 687.3 1,238.3 
65–74 327.6 134.2 47.4 509.2 398.0 184.1 153.6 735.7 1,245.0 
75–84 227.0 84.0 49.8 360.8 348.2 129.8 138.7 616.8 977.6 
85+ 55.4 10.8 11.6 77.8 111.7 35.3 41.2 188.2 266.0 
Total 1,461.2 696.8 286.4 2,444.5 1,629.9 979.9 635.4 3,245.2 5,689.7 
Note: See Figure 5.3. 
Source: Disease Expenditure Database, AIHW. 
 
Table C7: Expenditure for osteoarthritis by health-care sectors, age and sex, 2008–09 ($ million) 
Age 
group 
(years) 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
males 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
females 
Total 
persons 
Males Females  
0–4 0.0 0.0 0.1 0.1 0.0 0.0 0.7 0.7 0.8 
5–14 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.4 
15–24 1.0 0.4 0.1 1.5 0.5 1.1 0.1 1.7 3.4 
25–34 3.3 1.3 0.2 4.8 2.0 0.9 0.5 3.6 8.2 
35–44 14.2 5.4 1.2 20.8 9.8 5.3 1.7 16.8 37.7 
45–54 53.5 15.0 3.9 72.4 54.9 21.2 4.9 81.1 153.4 
55–64 150.3 28.4 8.4 187.1 171.6 43.6 13.1 228.3 415.5 
65–74 191.8 34.8 9.8 236.4 234.0 49.4 17.9 301.3 537.7 
75–84 123.6 25.1 9.2 158.1 189.1 36.7 18.0 243.8 401.8 
85+ 19.8 3.0 2.1 24.8 36.3 10.0 7.5 53.8 78.7 
Total 557.7 113.5 35.0 706.2 698.3 168.5 64.4 931.2 1,637.4 
Note: See Figure 5.4. 
Source: Disease Expenditure Database, AIHW. 
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Table C8: Expenditure for back problems, by health-care sector, age and sex, 2008–09 ($ million) 
Age 
group 
(years) 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
males 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines 
Total 
females 
Total 
persons 
Males Females  
0–4 0.4 0.3 0.8 1.5 0.3 0.0 0.5 0.9 2.4 
5–14 0.6 1.6 0.0 2.2 0.9 1.4 0.0 2.4 4.6 
15–24 3.8 7.7 0.9 12.5 4.3 8.5 1.0 13.9 26.3 
25–34 17.7 14.6 3.9 36.2 14.4 21.0 4.7 40.1 76.3 
35–44 40.1 31.3 10.8 82.3 33.9 38.7 10.0 82.6 164.9 
45–54 49.6 45.6 16.8 112.0 46.9 54.8 17.1 118.9 230.9 
55–64 53.4 45.2 14.3 112.9 52.5 54.0 16.2 122.6 235.5 
65–74 48.3 34.7 8.9 91.9 57.2 44.1 15.8 117.1 209.0 
75–84 38.7 19.9 7.9 66.5 59.4 29.4 15.6 104.5 171.0 
85+ 12.3 3.5 2.1 17.9 25.4 8.1 5.1 38.6 56.5 
Total 264.9 204.5 66.5 535.9 295.3 260.1 86.1 641.5 1,177.4 
Note: See Figure 5.5. 
Source: Disease Expenditure Database, AIHW. 
Table C9: Expenditure for rheumatoid arthritis, by health-care sectors, age and sex, 2008–09  
($ million) 
Age 
group 
(years) 
Admitted 
patient 
costs 
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines 
Total 
males 
Admitted 
patient 
costs 
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines 
Total 
females 
Total 
persons 
Males Females  
0–4 0.1 0.0 0.1 0.1 0.5 0.0 0.6 1.1 1.2 
5–14 0.7 0.3 0.5 1.5 1.1 0.1 4.5 5.8 7.2 
15–24 0.4 0.3 2.0 2.8 0.8 0.6 0.6 2.0 4.8 
25–34 0.3 0.1 0.0 0.4 1.0 1.3 4.9 7.3 7.7 
35–44 0.9 1.1 2.8 4.8 1.9 1.2 7.9 11.1 15..9 
45–54 1.5 1.6 30.4 33.5 4.7 4.5 40.4 49.6 83.1 
55–64 3.0 4.0 27.4 34.4 8.1 7.8 43.4 59.3 93.8 
65–74 2.8 2.0 9.6 14.4 7.5 5.3 62.9 75.7 90.2 
75–84 1.6 1.6 8.8 11.9 5.5 4.1 24.8 34.4 46.3 
85+ 0.2 0.3 0.8 1.4 1.1 0.5 2.2 3.8 5.2 
Total 11.7 11.2 82.5 105.3 32.3 25.4 192.2 249.9 355.2 
Note: See Figure 5.6. 
Source: Disease Expenditure Database, AIHW. 
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Table C10: Expenditure for osteoporosis, by health-care sectors, age and sex, 2008–09 ($ million) 
Age 
group 
(years) 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
males 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
females 
Total 
persons 
Males Females  
0–4 0.0 0.0 0.2 0.2 0.0 0.0 0.9 0.9 1.1 
5–14 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.2 
15–24 0.1 0.0 0.0 0.1 0.1 0.2 0.6 0.9 1.0 
25–34 0.1 0.1 0.0 0.1 0.1 0.2 0.2 0.5 0.6 
35–44 0.3 0.3 0.5 1.1 0.3 0.8 0.8 1.9 3.0 
45–54 0.6 0.7 1.4 2.7 0.7 2.6 8.3 11.6 14.3 
55–64 1.1 1.7 2.4 5.2 2.0 17.5 27.4 46.9 52.1 
65–74 1.5 3.5 8.6 13.6 5.0 15.4 43.2 63.6 77.3 
75–84 2.8 4.3 11.2 18.3 14.0 14.1 63.0 91.1 109.4 
85+ 2.3 0.8 4.8 7.9 12.2 5.9 21.0 39.1 47.0 
Total 8.8 11.5 29.1 49.4 34.5 56.7 165.4 256.6 306.0 
Note: See Figure 5.7. 
Source: Disease Expenditure Database, AIHW. 
 
Table C11: Expenditure for other musculoskeletal conditions, by health-care sectors, age and sex, 
2008–09 ($ million) 
Age 
group 
(years) 
Admitted 
patient 
costs  
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
males 
Admitted 
patient 
costs 
Out-of-
hospital 
medical 
expenses 
Prescription 
medicines  
Total 
females 
Total 
persons 
Males Females  
0–4 8.4 1.9 0.5 10.8 6.8 7.1 42.2 56.1 66.9 
5–14 29.6 14.8 0.2 44.6 31.5 11.0 0.2 42.7 87.3 
15–24 64.3 22.1 1.2 87.6 40.5 25.3 1.3 67.2 154.7 
25–34 64.3 29.3 3.3 97.0 35.6 28.7 4.0 68.2 165.2 
35–44 80.2 53.6 7.3 141.2 54.7 66.9 9.9 131.5 272.7 
45–54 98.2 62.3 10.2 170.7 82.9 98.2 15.0 196.1 366.8 
55–64 108.9 76.7 25.8 211.3 106.3 105.9 17.9 230.1 441.4 
65–74 83.2 59.2 10.5 152.9 94.3 69.8 13.9 178.0 330.9 
75–84 60.2 33.1 12.7 106.0 80.2 45.5 17.4 143.1 249.1 
85+ 20.8 3.1 1.7 25.7 36.7 10.8 5.4 53.0 78.7 
Total 618.2 356.1 73.4 1,047.6 569.5 469.2 127.4 1,165.1 2,213.7 
Source: Disease Expenditure Database, AIHW. 
 
  
 40 Health-care expenditure on arthritis and other musculoskeletal conditions 2008–09 
Table C12: Health-care expenditure per person for different arthritis and other musculoskeletal 
conditions, by age and sex, 2008–09 ($ million) 
Sex Age group 
(years) 
All arthritis 
and other 
musculo-
skeletal 
conditions 
Osteo-
arthritis 
Rheumatoid 
arthritis 
Back 
problems 
Osteo-
porosis 
Other 
musculo-
skeletal 
conditions 
Male 0–4 17.6 0.1 0.2 2.1 0.3 15.0 
 5–14 34.7 0.0 1.1 1.6 0.1 31.9 
 15–24 67.6 1.0 1.8 8.1 0.1 56.7 
 25–34 91.5 3.2 0.3 23.9 0.1 64.0 
 35–44 162.3 13.5 3.1 53.4 0.7 91.6 
 45–54 266.5 49.3 22.8 76.3 1.8 116.3 
 55–64 457.1 155.2 28.6 93.6 4.3 175.3 
 65–74 684.0 317.5 19.4 123.4 18.3 205.4 
 75–84 839.0 367.4 27.8 154.7 42.6 246.6 
 85+ 645.5 206.9 11.3 148.8 65.3 213.2 
 Total 228.7 66.1 9.9 50.1 4.6 98.0 
Female 0–4 87.2 1.0 1.6 1.3 1.3 82.0 
 5–14 38.6 0.3 4.3 1.8 0.1 32.2 
 15–24 58.6 1.2 1.4 9.5 0.6 45.9 
 25–34 80.0 2.3 4.9 26.8 0.3 45.7 
 35–44 156.0 10.8 7.1 52.8 1.2 84.1 
 45–54 306.2 54.3 33.2 79.6 7.8 131.4 
 55–64 567.5 188.5 49.0 101.2 38.7 190.0 
 65–74 953.8 390.6 98.2 151.8 82.5 230.7 
 75–84 1141.0 451.0 63.6 193.2 168.4 264.7 
 85+ 787.6 225.0 15.8 161.5 163.7 221.7 
 Total 300.9 86.3 23.2 59.5 23.8 108.1 
Persons 0–4 51.5 0.6 0.9 1.7 0.8 47.6 
 5–14 36.6 0.1 2.6 1.7 0.1 32.0 
 15–24 63.2 1.1 1.6 8.8 0.3 51.4 
 25–34 85.8 2.7 2.6 25.4 0.2 54.9 
 35–44 159.1 12.1 5.1 53.1 1.0 87.8 
 45–54 286.5 51.8 28.1 78.0 4.8 123.9 
 55–64 512.4 171.9 38.8 97.4 21.6 182.7 
 65–74 821.3 354.7 59.5 137.9 51.0 218.3 
 75–84 1007.2 414.0 47.7 176.2 112.7 256.7 
 85+ 740.0 219.0 14.3 157.2 130.7 218.8 
 Total 264.9 76.2 16.5 54.8 14.2 103.1 
Source: Disease Expenditure Database, AIHW. 
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Table C13: Allocated health-care expenditure in current and constant prices, Australia, by year  
($ million) 
Year  
Total expenditure Total expenditure Expenditure on arthritis 
and other musculoskeletal 
conditions 
Arthritis and other 
musculoskeletal conditions as 
% of total expenditure 
(current prices) (2008–09 prices) (2008–09 prices) (2008–09 prices) 
2000–01 33,882 42,915 3,411 7.9 
2004–05 44,265 49,756 4,345 8.7 
2008–09 65,129 65,129 5,690 8.7 
Note: Only includes expenditure for hospital admitted patients, out-of-hospital medical expenses and prescription pharmaceuticals. 
Source: Disease Expenditure Database, AIHW. 
 
Table C14: Constant price estimates, arthritis and other musculoskeletal conditions, by health-care 
sectors, 2000–01, 2004–05 and 2008–09 ($ million) 
Health-care sector  
2000–01 2004–05 2008–09 
$m 
Hospital admitted patient 
services 1,673 2,316 3,091 
Out-of-hospital medical 
expenses 1,264 1,341 1,677 
Prescription pharmaceuticals 475 687 922 
Total expenditure allocated 
for arthritis and other 
musculoskeletal conditions 3,411 4,345 5,690 
Note: See Figure 6.1. 
Source: Disease Expenditure Database, AIHW. 
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Glossary 
allied health practitioners: For the purpose of this report, allied health practitioners are 
those registered under the National Registration Accreditation Scheme. They include 
professionals working in psychology, pharmacy, physiotherapy, occupational therapy, 
radiography, optometry, chiropractor, Chinese medicine, podiatry, osteopathy and 
Aboriginal and Torres Strait Islander health practitioners. 
allocated health-care expenditure: The spending on health goods and services that can be 
allocated by a specific disease type. Unless otherwise specified, ‘expenditure’ in this report 
refers to allocated health-care expenditure. 
arthritis: A group of disorders in which there is inflammation of the joints, which can 
become stiff, painful, swollen or deformed. The two main types of arthritis are osteoarthritis 
and rheumatoid arthritis. 
biologic disease-modifying anti rheumatic drugs: bDMARDs help to reduce the symptoms 
of rheumatoid arthritis by targeting the body’s own immune system, to slow down the 
inflammation process and stop the progression of joint damage. Such medications are 
injected or given intravenously. 
capital expenditure: Spending (expenditure) on large-scale fixed assets (for example, new 
buildings and equipment with a useful life extending over a number of years). 
constant prices: Dollar amounts for different years that are adjusted to reflect the prices in a 
chosen reference year. This provides a way of comparing spending over time on an equal 
value-for-value basis without the distorting effects of inflation. The comparison will reflect 
only the changes in the amount of goods and services purchased—changes in the ‘buying 
power’—not the changes in prices of these goods and services caused by inflation.  
current prices: Dollar amounts reported for a particular year, unadjusted for inflation. 
Changes in current price expenditures reflect changes in both price and volume.  
disease-modifying anti-rheumatic drugs: DMARDs help to prevent joint and cartilage 
damage and may produce major improvement in rheumatoid arthritis patients. 
hospital admitted patient: A patient who undergoes a hospital’s formal admission process 
to receive treatment and/or care. This treatment and/or care is/are provided over a period 
of time and can occur in hospital and/or in the person’s home (for hospital-in-the-home 
patients). 
Hospitalisation: Hospitalisation is synonymous with admission and separation; that is, it is 
an episode of hospital care that starts with the formal admission process and ends with the 
formal separation process. 
inflammation: Local response to injury or infection, marked by local redness, heat, swelling 
and pain. Can also occur when there is no clear external cause and the body reacts against 
itself, as in auto-immune diseases. 
International Classification of Diseases: The World Health Organization’s internationally 
accepted classification of death and disease. The 10th revision (ICD-10) is currently in use. 
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ICD-10-AM is the Australian modification of ICD-10, used for diagnoses recorded for 
patients admitted to hospitals. 
minimal trauma fracture: Refers to a type of pathological fracture that occurs as a result of a 
fall from standing height or less. 
musculoskeletal: Relating to the muscles, joints and bones. 
non-admitted patient: A patient who receives care from a recognised non-admitted patient 
service/clinic of a hospital, including emergency departments and outpatient clinics. 
non-steroidal anti-inflammatory drugs: NSAIDS are drugs that reduce pain and 
inflammation. 
out-of-hospital medical expenses: The cost for services provided by, or on behalf of, 
registered medical practitioners to non-admitted patients. These expenses include the cost of 
consultations and services such as imaging, pathology and diagnostic services. 
out-of-pocket costs: The total costs incurred by individuals for health-care services over and 
above any refunds from Medicare and private health insurance funds. 
Pharmaceutical Benefits Scheme: A national, government-funded scheme that subsidises 
the cost of a wide range of pharmaceutical drugs for all Australians to help them afford 
standard medications. 
prescription pharmaceuticals: Medicines available only on the prescription of a registered 
medical or dental practitioner and available only from pharmacies.  
prevalence: The number or proportion (of cases, instances, and so forth) in a population at a 
given time. 
principal diagnosis: The diagnosis listed in hospital records to describe the problem that 
was chiefly responsible for hospitalisation. 
recurrent spending: Spending (expenditure) on goods and services that are used during the 
year (for example, salaries). It may be contrasted with capital spending. See ‘capital 
spending’ above. 
Repatriation Pharmaceutical Benefits Scheme: This scheme assists eligible veterans (with 
recognised war or service-related disabilities) and their dependants for both pharmaceuticals 
listed on the PBS and a supplementary repatriation list, at the same cost as for patients 
entitled to the concessional payment under the PBS. 
Separation: The formal process where a hospital records the completion of an episode of 
treatment and/or care for an admitted patient. In this report, it is described by the term 
‘hospitalisation’. See ‘hospitalisation’ above. 
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Arthritis and other musculoskeletal conditions are 
substantial contributors to health-care expenditure in 
Australia. in 2008–09, estimated health-care expenditure 
allocated to these conditions totalled $5,690 million—
the 4th most expensive disease group, accounting 
for 8.7% of total health-care expenditure allocated to 
disease groups.
this report is the latest in a series on arthritis and 
other musculoskeletal conditions expenditure. the key 
objectives of this report are to describe the distribution 
of health-care expenditure by health-care sector for 
the major musculoskeletal conditions: osteoarthritis, 
rheumatoid arthritis, back problems and osteoporosis.
